Ancient immune protein C3 boosts cancer immunotherapy within tumors

Ancient molecule made inside tumors drives immune response, study finds

An ancient molecule that existed long before the circulatory system evolved has been found to support cancer immunotherapy. Researchers at Nagoya University in Japan found that complement C3 protein acts inside tumors to prevent the accumulation of immunosuppressive cells, but only when produced inside the tumor. C3 circulating in the blood did not affect treatment outcomes.

Ancient immune protein C3 boosts cancer immunotherapy within tumors

An ancient molecule that existed long before the blood circulation system evolved, has been found to support cancer immunotherapy.

Immune cells in the tumour microenvironment: Better near than far away?

A study led by Universitat Pompeu Fabra (UPF) on immune cells in the tumour microenvironment describes the relationship between the proximity of lymphocytes to the blood supply and their functional capacity.

Autoantibodies Could Play Key Role in Cancer Progression and Prevention

Scientists have long sought to understand why some people with no known risk factors develop cancer while others with significant risk never do. The answer may lie in immune proteins known as autoantibodies (auto-Abs), suggests a commentary in Cell co-authored by a team that includes Jean-Laurent Casanova, M.D., Ph.D., Professor in the Center for the Genetics of Host Defense and Children’s Medical Center Research Institute at UT Southwestern (CRI).

Ancient Protein Aids in Anti-Cancer Immunity

Artificially Recreating C3 Effects Overcomes Resistance in Hard-to-Treat Tumors

An ancient molecule that existed long before the blood circulation system evolved, has been found to support cancer immunotherapy. Researchers at Nagoya University in Japan found that complement C3 protein acts inside tumors to prevent the accumulation of immunosuppressive cells, but only when produced inside the tumor.